Asia-Pacific Anesthesia Drugs Market - Growth, Trends, and Forecasts 2017 - 2022

  • ID: 4388623
  • Report
  • Region: Asia Pacific
  • 201 pages
  • Mordor Intelligence
1 of 4
The Asia-Pacific anesthetic drugs market accounted for USD 3,360 million in 2015 and USD 3,459 million in 2016. The market is expected to reach USD 3,990 million by 2021, growing at a CAGR of 2.9% during the forecast period of 2016 to 2021.

While the general anesthetic drugs induce a complete lack of sensation, local anesthetics drugs target only a specific region. Local anesthetics are much safer to use and also have fewer side-effects compared to general anesthetics.

The advancement in surgical procedures, increasing cosmetic and orthopedic surgeries and the high incidence of emergency surgical procedures and critical care are propelling the growth of the market. However, side-effects of general anesthetics, lack of skilled anesthesiologists and regulatory issues are turning out to be the restraints for the market.

The Asia-Pacific anesthesia drugs market has been segmented by the type into general and local anesthetics. The general anesthetics segment is further subdivided into most-used and popular drugs. These include Sevoflurane, Propofol, Desflurane, Dexmedetomidine, Isoflurane, Midazolam and others. The segment on local anesthetics includes Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Oxethazaine, Prilocaine, Benzocaine and other local anesthetics. The segmentation based on the route of delivery includes inhalation and injection. Amongst general anesthetics, the market for Propofol is expected to dominate the market throughout the forecast period. Amongst local anesthetics, Ropivacaine is expected to dominate the market.

Geographically, the Asia-Pacific market has been segmented into India, China, Japan, South Korea, Australia & New Zealand and Rest of Asia-Pacific. China's anesthesia market is the largest market in the Asia-Pacific region.

Major Companies in the Sector Include:

This Report Offers:

Market analysis for the Asia-Pacific anesthetic drugs market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the Asia-Pacific anesthetic drugs market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Study deliverables
1.2 Market definition
1.3 Study assumptions
2. Research approach and methodology
2.1 Introduction
2.2 Analysis methodology
2.3 Study timeline
2.4 Study phases
2.4.1 Secondary research
2.4.2 Discussion guide
2.4.3 Market engineering & econometric model
2.4.4 Expert validation
3. Executive summary
4. Key inferences
5. Market overview and industry trends
5.1 Current market scenario
5.2 Porter's five forces
5.2.1 Bargaining power of suppliers
5.2.2 Bargaining power of consumers
5.2.3 Threat to new entrants
5.2.4 Threat to substitute products and services
5.2.5 Competitive rivalry within the industry
6. Market drivers, restraints, challenges, and opportunities
6.1 Market drivers
6.1.1 Rising number of surgeries
6.1.2 New approvals of anesthetic drugs
6.1.3 Increase in number of cosmetic surgeries
6.1.4 Emerging Economy
6.2 Market restraints
6.2.1 Side effects of general anesthetics
6.2.2 Lack of skilled anesthesiologists
6.2.3 Regulatory issues
6.3 Market opportunity
6.4 Market challenge
7. Market segmentation
7.1 By product
7.1.1 General anesthetics
7.1.1.1 Propofol
7.1.1.2 Sevoflurane
7.1.1.3 Desflurane
7.1.1.4 Dexmedetomidine
7.1.1.5 Remifentanil
7.1.1.6 Midazolam
7.1.1.7 Others
7.1.2 Local anesthetics
7.1.2.1 Bupivacaine
7.1.2.2 Ropivacaine
7.1.2.3 Lidocaine
7.1.2.4 Chloroprocaine
7.1.2.5 Oxethazaine
7.1.2.6 Prilocaine
7.1.2.7 Benzocaine
7.1.2.8 Other local anesthetics
7.2 By application
7.2.1 General anesthetics
7.2.2 Plastic Surgery
7.2.3 Cosmetics
7.2.4 Dental Anesthetics
7.2.5 Spinal anesthetics
7.2.6 Peripheral nerve block
7.2.7 Epidural
7.2.8 Interscalene block
7.2.9 Saddle block
7.2.10 Others
7.3 By route of administration
7.3.1 Inhalation
7.3.2 Injection

8. Market segmentation by geography
8.1 Asia-Pacific (APAC)
8.1.1 Introduction
8.1.2 China
8.1.3 Japan
8.1.4 India
8.1.5 Australia & New Zealand
8.1.6 South Korea
8.1.7 Rest of Asia-Pacific
9. Competitive landscape
9.1 Merger and acquisition analysis
9.2 New product launches
9.3 Agreements, collaborations, and partnerships
10. Company profiles
10.1 Baxter
10.2 Hospira
10.3 Abbott
10.4 Astra Zeneca
10.5 Roche
10.6 Novartis
10.7 Pfizer
10.8 Eisai
10.9 Piramal Healthcare
10.10 Hikma Pharmaceuticals
11. Future outlook for investment opportunity
12. Analyst outlook of the market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll